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Background  26 
The 2013-2016 West African Ebola outbreak left a record number of Ebola survivors, and this has been 27 
added to in subsequent outbreaks. A range of post-Ebola sequelae in survivors have been reported, but 28 
little is known about subsequent mortality of those discharged from Ebola Treatment Units (ETU).  29 
Methods 30 
The Guinean national survivors’ monitoring program (SA-Ceint) contacted all survivors and recorded 31 
deaths from December 2015. Survivors were followed up until September 2016, a mean of 21 months 32 
after ETU discharge. Deaths were investigated using verbal autopsy. We calculated the age-standardised 33 
mortality ratio compared to the Guinean population, and assessed risk factors for mortality using 34 
survival analysis and Cox regression. 35 
Findings 36 
Information was retrieved on 1130/1270 Guinean Ebola virus disease survivors (follow-up rate 89%). 37 
Survivors had an over five-fold increased risk of dying, compared to the Guinean population (age-38 
standardised mortality ratio 5.2, 95% CI 4.0-6.8), a mean of one year of follow-up after ETU discharge, 39 
with no increase in risk for the subsequent 9 months. Mortality rates were increased in all age groups 40 
and were similar for males and females. Of the 59 deaths, cause of death was tentatively attributed to 41 
renal failure for 37, usually based only on reported anuria. Cause of death was unknown for 7. Longer 42 
hospitalisation in the ETU was associated with an increased risk of late death. 43 
Interpretation  44 
The subsequent mortality rate in individuals who survived the acute phase of Ebola Virus Disease and 45 
were discharged from ETU was high. The finding that survivors that experienced longer hospitalisation 46 
had an increased risk of death, may be of help in the set-up of current and future survivors’ programs 47 
and the prioritisation of funds in resource-constrained settings. The suggestion of renal failure as a 48 
potential contributor to the late deaths needs further investigation. 49 
Funding 50 
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Research in context  53 
Evidence before this study  54 
Little evidence exists on the subsequent mortality rate in people surviving Ebola. Up to April, 4th, 2019, 55 
we used the following search string for a PubMed search: (Ebola OR ebolavirus) AND (survivor) AND 56 
(death OR mortality). The search yielded 68 citations. Of those, some reported post-Ebola sequelae and 57 
Ebola virus persistence in survivors’ body fluids; only one study looked at late deaths among Ebola 58 
survivors, and reported 4 deaths out of 151 survivors who were followed-up for a mean time of 10 59 
months. 60 
Added value of this study 61 
This is the largest study, and the first nationwide cohort study to report subsequent mortality of people 62 
who survived Ebola virus disease (EVD). We report high mortality among Ebola survivors in Guinea, 63 
with an age-standardised mortality rate over five times that of the general population in the first year. 64 
Mortality was higher in survivors who spent longer in an Ebola treatment unit, , possibly highlighting a 65 
higher-risk group within the cohort of Ebola survivors. Renal failure was tentatively suggested as a 66 
contributor to more than half the deaths. 67 
Implications of all available evidence  68 
The increased mortality among survivors is alarming: future studies aimed at establishing whether renal 69 
failure may be a long-term effect of EVD are warranted. This study confirms the high vulnerability of 70 
Ebola survivors, particularly those with more prolonged acute disease, and suggests an underestimation 71 
of the overall EVD case fatality rate. 72 
  73 




The Ebola virus disease (EVD) epidemic in West Africa caused ~28,616 cases and ~11,310 deaths. As 75 
a result, West Africa has the biggest cohort of EVD survivors (hereafter survivors) in history – over 76 
17,000 individuals. 1  77 
Ebola sequelae were reported by cohort studies of survivors of the 1995 Kikwit EVD outbreak, and 78 
included arthralgia, myalgia, abdominal pain, fatigue, anorexia and late ocular complications. 2–4 Studies 79 
from subsequent outbreaks, including the 2013-2016 outbreak in West Africa, have confirmed that many 80 
EVD survivors suffer from a broad range of sequelae, which also include hearing loss and neurological 81 
signs.5–10 A large cohort study from Liberia has reported that symptoms such as urinary frequency, 82 
headache, memory loss, fatigue, joint pain and muscle pain were more frequent among survivors than 83 
controls (ie antibody-negative close contacts).11 Long viral persistence in semen and other bodily fluids 84 
of survivors can occasionally cause EVD recrudescence in the individual, and EVD re-emergence in the 85 
community by infecting other people. 11–15 86 
Despite the extensive literature on Ebola sequelae, little information is available on deaths occurring 87 
after discharge from Ebola Treatment Units (ETU) in cohorts of EVD survivors. A study in Sierra Leone 88 
followed up 151 survivors at a mean time of 10 months after discharge from an ETU and reported the 89 
death of four of them, all within 6 weeks of discharge.16 90 
Initially, survivors in Guinea were followed up mainly within research-focused cohort studies and no 91 
exhaustive national cohort was established.9,17–20 The World Health Organization (WHO) advised that 92 
an intensive integrated program was necessary to address the medical and psychosocial needs of 93 
survivors as well as the risk of virus reintroduction, ideally to be integrated into existing routine health 94 
services and facilities.21 Therefore, the national coordination for the fight against EVD (Coordination 95 
National pour la Lutte contre le virus Ebola, CNLEB), WHO Country office, and its partners, developed 96 
and implemented a community monitoring program for EVD survivors, called SA-Ceint (from 97 
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‘Surveillance Active en ceinture’; ie cordon sanitaire), to follow  survivors closely with the aim of 98 
avoiding Ebola virus reintroduction into the community. 99 
Using these national level data, we estimate the standardised mortality ratio of EVD survivors in Guinea, 100 
describe the potential contributors to the deaths identified during death investigations, and report on the 101 
risk factors associated with death after ETU discharge. 102 
 103 
Methods 104 
Study design and participants 105 
The names and contacts of all eligible survivors were identified from the EVD database managed by the 106 
Ministry of Health (MoH) and partners. All survivors were eligible to participate in the SA-Ceint 107 
program if they were able to show the certificate of medical clearance that they were given at discharge 108 
from the ETU. From December, 2015, the teams of the survivors’ monitoring program attempted to 109 
contact all EVD survivors, and classified them as: i) willing to participate, ii) lost to follow-up, and iii) 110 
reportedly dead. For those who were reported to have died, a field team was in charge of the death 111 
investigation. The closest member of the family completed a verbal autopsy. Verbal autopsy interviews 112 
collect a description of illness and events and a checklist of symptoms. WHO medical epidemiologists 113 
in charge of the death investigation suggested the main contributor to death based on the verbal autopsy 114 
and medical files shared by the family member, when available. Each cause of death was reviewed and 115 
validated by a panel of experts from WHO and the MoH. The survivors who responded were actively 116 
followed up from January 1st until September 30th, 2016, which corresponded to at least one year after 117 
discharge from the ETU for over 99% of survivors. All participants received a monthly allowance, 118 
including free cell phone with monthly credit, as well as other forms of support (such as rice and flour) 119 
as part of the survivor package. 120 
Statistical analysis 121 
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For all statistical analyses, we used the official MoH Ebola virus database that was curated in 122 
collaboration with WHO and other partners. This database was used for notification purposes during 123 
the outbreak and reviewed on a weekly basis; it contained complete epidemiological information 124 
available to the MoH and  information on laboratory confirmation (yes/no) for all suspected, probable 125 
and confirmed cases of EVD in Guinea.  126 
The outcome of this analysis, late death, was defined as death from any cause after ETU discharge. 127 
Independent variables (age group, sex, number of days of hospitalisation, date of ETU discharge and 128 
area of residence) were recorded as at ETU discharge. Categorical variables were reported using 129 
numbers and percentages and compared by the Pearson’s chi-squared test. Date of ETU discharge was 130 
divided in four categories based on the median and interquartile range dates.  Duration of 131 
hospitalisation was divided in number of days above or below the median. Missing observations for 132 
this variable were included in the Cox regression models as unknown. Survival of the participants by 133 
each independent variable was compared using the log-rank test.  134 
For the survival analysis, the observation period was calculated from the date of ETU discharge, 135 
available for all survivors, to the date of death or the date of the end of the SA-Ceint program 136 
(September 30th, 2016). All deaths of survivors with unknown date of death occurred by December, 137 
31st, 2015. Therefore, we used the midpoint between ETU discharge and December 31st, 2015 as an 138 
estimate of the date of death. 139 
The standardised mortality ratio (SMR) was calculated using indirect standardization. Since the risk of 140 
death associated with Ebola is likely to decrease over time, we calculated SMR for two different periods: 141 
from ETU discharge until December 31st, 2015 (the date by which all deaths with unknown dates had 142 
occurred), corresponding to a mean of 12.6 months of follow-up (range 2 days-23.8 months), and from 143 
January 1st to September 30th, 2016, a mean of 8.9 months of follow-up (range 1.1-9.0 months) The age-144 
specific mortality rates in the Guinean population from the third General Population and Housing Census 145 
(RGPH3), National Institute for Statistics (2014),22 and the number of survivors by age group in the 146 
 Page 8 
 
 
study population were used to calculate the age-specific expected deaths. These were then compared to 147 
the age-specific observed deaths to derive the SMR.  148 
A multivariable proportional hazards (Cox) regression model was constructed to identify factors 149 
associated with late death. Variables giving p<0.2 in the log-rank test were included in the first model, 150 
and variables with likelihood ratio test p-value<0.1 were kept in the final model.  The proportionality 151 
assumption was checked using the Schoenfeld and scaled Schoenfeld residuals’ test and no violation 152 
of the final model’s proportionality was found. The goodness of fit of the final model was evaluated 153 
by the Cox-Snell residuals. All tests were two sided with 95% confidence interval (CI), and analyses 154 
were performed using STATA (version14, StataCorp, LP, TX, USA) software. 155 
Analyses were repeated calculating the person-years at risk for those whose date of death was 156 
unknown in two ways: i) as if they all died the day after ETU discharge (shortest possible delay of a 157 
late death), ii) as if they all died on December 31st, 2015 (earliest date by which all deaths with 158 
unknown date of death were confirmed). A complete case analysis was also carried out including only 159 
those with known dates of death, and known duration of hospitalization. 160 
 161 
Ethics approval and consent to participate 162 
This study is an analysis of data collected from the SA-Ceint program, which was implemented 163 
following the guidelines from the WHO Ebola response phase 3 strategic document. The SA-Ceint 164 
program was integrated in the workflow of other research projects, i.e. Postebogui, the JIKI trial, 165 
EBOSEX, and Ebola ça suffit vaccination trial, that were all approved by the National Committee 166 
for Ethics in Research and Health (CNERS) before their start.  All the participants signed a written 167 
informed consent at the beginning of this study.  168 
 169 
Role of the funding source 170 
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The funders of the study had no role in study design, data collection, data analysis, data 171 
interpretation, or writing of the report. The corresponding author had full access to all the data in 172 
the study and had final responsibility for the decision to submit for publication. 173 
 174 
Results 175 
Characteristics of study participants  176 
We aimed to enroll all survivors of the 2013-2016 EVD outbreak in Guinea (N=1270). Of these, 140 177 
were lost to follow-up (follow-up rate 89%, Figure). Fifty-five individuals were reported to have died 178 
between ETU discharge and when they were first sought for this study, and 4 more died during follow-179 
up. The characteristics of the survivors, including those lost to follow-up, and those who subsequently 180 
died, are shown in Table 1. The baseline characteristics of those who were lost to follow-up were similar 181 
to those who were followed up except for area of residence and month of ETU discharge (Table 1). 182 
Among those for whom follow-up information was available, half (610) were female and the median 183 
age at ETU discharge was 28 years (range 1 month - 90 years). Twenty-one per cent were from Conakry 184 
(240/1130). The median number of days hospitalised was 12 (IQR 9-15), and was missing for 6% of 185 
survivors (73/1130), because date of admission was missing.  186 
Because of the retrospective nature of the cohort study, for 43/59 deaths we only knew that death 187 
occurred between the date of ETU discharge and December 31st, 2015. Among the 16 survivors for 188 
whom we were able to retrieve the exact date of death, five died within a month following ETU discharge 189 
(at 2, 6, 10, 14 and 30 days), three died within the first 3 months after ETU discharge (at 53, 57 and 87 190 
days), four died 3-12 months after ETU discharge (at 5, 6, 6 and 10 months), and four more than a year 191 
after ETU discharge (at 16, 17, 19 and 21 months).  192 
Age-specific mortality rates and age-standardised mortality ratio  193 
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The mean follow-up time for the 1130 survivors was 21.2 months. The shortest follow-up among those 194 
who did not die was 5.4 months, and the longest 32.7 months. Total follow-up time was 1987.4 person-195 
years. The mortality rate varied by age, being higher in those over 55 (Table 2). To account for 196 
background mortality the observed deaths were compared to the number of deaths expected according 197 
to the Guinea 2014 census.22 There were more observed deaths than expected deaths at all ages; the ratio 198 
between observed and expected deaths varied by age, but with no consistent pattern (Table 3). It was 199 
highest at age 5-14 and lowest in the under 5s. For the period until December 2015, EVD survivors had 200 
over five times greater risk of death than the Guinean population (SMR 5.2, 95% CI 4.2-7.2, Table 3). 201 
For the period between January 1st and September 30th, 2016, the SMR was 0.6 (95% CI 0.2-1.4). Those 202 
with unknown dates of death contributed 23.0 person years at risk in the main analysis. Taking extreme 203 
values (assuming all deaths were early or all were late), the SMR for the first period hardly changed 204 
(SMR estimates = 5.4 and 5.1, respectively). 205 
 206 
Risk factors for late death among survivors 207 
The post-ETU mortality rate was similar in males and females and in those seen at different stages of 208 
the epidemic. It was lower in Conakry than elsewhere, and was higher in those with longer stays in the 209 
ETU (Table 1). We used a Cox regression model to identify potential risk factors for death after ETU 210 
discharge. Age, area of residence and duration of stay in the ETU were independently associated with 211 
mortality (Table 4). Survivors who were hospitalised for ≥12 days during their episode of Ebola virus 212 
infection had over twice the risk of late death compared to those hospitalised less than 12 days (adjusted 213 
HR 2.62, 95% CI 1.43-4.79). Taking extreme values for the dates of death of those with unknown 214 
dates, and the complete case analysis gave similar results (Supplementary Table).  215 
 216 
Investigations of cause of late death of Ebola virus disease survivors 217 
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We could gather limited information on possible cause of death for 52/59 reported deaths. Unfortunately, 218 
due to data management challenges encountered in Guinea, we were unable to link this information to 219 
each study participant and the medical files reviewed for each death are no longer available. In over half 220 
of the late deaths (37/59), a role of renal failure was evoked by a team of medical epidemiologists who 221 
reviewed the available medical files and the verbal autopsy completed by a family member. Of those 222 
deaths, three were reported by the Centre of haemodialysis of the main hospital in Conakry, where the 223 
survivors were hospitalised when they died. Most of the rest of the purported renal failure verbal autopsy 224 
diagnoses were based on anuria declared by the family or on creatinine levels. Other conditions that 225 
were judged to have a main role in the late deaths were malaria (5) pulmonary tuberculosis (3) high 226 
blood pressure (3), septicemia (1), brain tumor (1), accident (1) and suicide (1).  227 
Discussion 228 
Though much is known about sequelae caused by EVD, little was known before this study about the 229 
risk of death among the Ebola virus disease survivors.  Here, we report an unexpectedly high mortality 230 
among EVD survivors in Guinea. Among the risk factors we were able to investigate, we found a higher 231 
risk among survivors who had longer stays in the ETU and in older adults. 232 
Bower et al. reported four late deaths among 151 survivors from Sierra Leone with a mean follow-up of 233 
10 months (2.6%).16 This is consistent with our overall risk of death (5.2% with a mean follow-up of 21 234 
months). Mortality rates were not constant over time. All 4 deaths in Sierra Leone occurred within the 235 
first 6 weeks. In our study the date of death was only known for 16: half died within the first 3 months, 236 
and 11 within 10 months. Almost all the deaths (55/59) had occurred by 31st December 2015, a mean of 237 
12.6 months after ETU discharge, giving a mean mortality risk of 4.9% by this time.   It is possible that 238 
the true mortality rate was higher, as mortality is likely to have been higher among those lost to follow-239 
up. 240 
For the first year of follow-up, the mortality rate we measured was over five times that expected in the 241 
Guinean population, having adjusted for age. For the subsequent 9 months, the SMR among survivors 242 
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was not significantly higher than in the general population. This is in line with observations from a 243 
cohort study that recruited Liberian survivors on average a year after ETU discharge, and found no 244 
increased risk of death compared to controls.11 The data we used for the comparison of mortality rates 245 
were representative of the Guinean population and came from the report on mortality of the latest 246 
available census (2014). This census was undertaken by the Guinean National Institute for Statistics 247 
under the technical assistance of experts of the United Nations Population Fund, and published in 2017.22 248 
A limitation of the census was that the number of deaths were not based on death records but 249 
extrapolated from the questionnaire given to the census study participants.  250 
Although poorer sections of the population, who would have higher background mortality rates, may 251 
have been more affected by Ebola, and so over-represented, this is unlikely to explain such a large 252 
increase in early mortality and is not supported by the mortality rates in 2016 . The lower risk of death 253 
among survivors residing in Conakry may be due to easier access to health care in the city, compared to 254 
non-urban areas. Limitations include that for most deaths date of death was missing, and that verbal 255 
autopsy and clinical data used to determine possible cause of death are no longer available. However, 256 
the distribution of deaths over time, and the possibility that renal failure contributed to over 60% of the 257 
deaths may suggest that the majority were linked to Ebola sequelae. 258 
While evidence of the role of renal failure is weak for most patients, it is biologically plausible.  EBOV 259 
is often detected in urine samples during the acute phase of the disease because it can infect the kidney, 260 
23 and EVD patients may develop acute kidney injury. 24,25 Acute kidney injury may lead to longer term 261 
renal failure and increased mortality rates even after initial apparent recovery.26,27  262 
This analysis used the data collected by the SA-Ceint program, so variables to investigate were limited 263 
to those collected for the program. No information about sequelae or exposure to drugs was available, 264 
so we could not further assess whether treatment was associated with adverse outcome, as tentatively 265 
observed by Etard et al. 9 The SA-Ceint program had an almost 90% follow-up rate among the survivors, 266 
which is a remarkable achievement. Of note, Guinea has many fewer survivors than Sierra Leone (over 267 
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10,000) and Liberia (almost 6,000), possibly explaining why the implementation of a nationwide follow-268 
up program with such a high follow-up rate may have been possible. 269 
However, Guinean health authorities encountered challenges in coordinating such a rapidly 270 
implemented program within a health system that was ravaged by the epidemic. An example is that 271 
although  the main contributor to death for EVD survivors was investigated and available for most 272 
deaths, we do not know on which data it was based, and the information to link it to the MoH database 273 
could not be retrieved.  274 
This study reveals that post-Ebola sequelae include an increased mortality rate. This demonstrates that 275 
survivors’ monitoring programs should be strengthened and should not exclusively focus on body fluid 276 
testing. Moreover, this study gives preliminary evidence that survivors hospitalised for longer periods 277 
may be particularly at risk and should be targeted, and, perhaps, that renal function should be monitored. 278 
Guidelines on how to implement such programs, to be followed by Ministries of Health of affected 279 
countries, are being constantly updated by a pool of Ebola experts coordinated by WHO.  280 
Future research should focus on the long-term effect of Ebola virus infection, including on the potential 281 
role of kidney function; illness duration and viral persistence in body fluids should be considered as 282 
potential risk factors in future epidemiological studies. 283 
In conclusion, we have shown a five-fold higher age-adjusted mortality rate among EVD survivors 284 
during the first year of follow-up, compared to the Guinean population. This study should be replicated 285 
in Sierra Leone and Liberia, and steps taken to understand, and, if possible, prevent these late deaths. 286 
  287 
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